ID
4848
Descripción
see http://clinicaltrials.gov/ct2/show/study/NCT00048295 ISIS 2302 is an antisense oligonucleotide drug that reduces the production of a specific protein called intercellular adhesion molecule (ICAM-1), a substance that plays a significant role in the increase of inflammation. People with Crohn’s disease have been shown to over-produce ICAM-1 in their gut tissues. Alicaforsen works by blocking ICAM-1 messenger RNA, the “instruction” molecule that is required for the production of ICAM-1 protein. This trial will examine effects of alicaforsen delivered by 2-hour intravenous infusion over a four-week period, compared to a placebo. Patients may remain on stable background 5-ASA, antibiotic, or immunosuppressive drugs, and prednisone (or equivalent) at </= 30 mg per day.
Link
http://clinicaltrials.gov/ct2/show/study/NCT00048295
Palabras clave
Versiones (1)
- 11/4/14 11/4/14 - Julian Varghese
Subido en
11 de abril de 2014
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Eligibility NCT00048295 Crohns Disease
Eligibility NCT00048295
- StudyEvent: Eligibility
Descripción
Exclusion
Descripción
Severe intestinal stenosis
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C0521587
Descripción
External fistulization
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C0016169
Descripción
Infection
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C0009450
Descripción
Malignancy
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C0006826
Descripción
Bleeding problem
Tipo de datos
boolean
Alias
- UMLS CUI-1
- C0005779
Similar models
Eligibility NCT00048295
- StudyEvent: Eligibility
C1456820 (UMLS CUI-2)
C0021469 (UMLS CUI-3)